HLS THERAPEUTICS INC (HLS.CA) Fundamental Analysis & Valuation

TSX:HLS • CA40390B1094

Current stock price

4.65 CAD
+0.1 (+2.2%)
Last:

This HLS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HLS.CA Profitability Analysis

1.1 Basic Checks

  • In the past year HLS has reported negative net income.
  • HLS had a positive operating cash flow in the past year.
  • In the past 5 years HLS always reported negative net income.
  • Each year in the past 5 years HLS had a positive operating cash flow.
HLS.CA Yearly Net Income VS EBIT VS OCF VS FCFHLS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

1.2 Ratios

  • HLS's Return On Assets of -9.04% is in line compared to the rest of the industry. HLS outperforms 43.75% of its industry peers.
  • Looking at the Return On Equity, with a value of -20.16%, HLS is in line with its industry, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
ROA -9.04%
ROE -20.16%
ROIC N/A
ROA(3y)-11.5%
ROA(5y)-9.8%
ROE(3y)-25.3%
ROE(5y)-20.57%
ROIC(3y)N/A
ROIC(5y)N/A
HLS.CA Yearly ROA, ROE, ROICHLS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20

1.3 Margins

  • Looking at the Gross Margin, with a value of 81.83%, HLS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • HLS's Gross Margin has declined in the last couple of years.
  • HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.78%
GM growth 5Y-2.65%
HLS.CA Yearly Profit, Operating, Gross MarginsHLS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. HLS.CA Health Analysis

2.1 Basic Checks

  • HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HLS has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HLS has less shares outstanding
  • Compared to 1 year ago, HLS has an improved debt to assets ratio.
HLS.CA Yearly Shares OutstandingHLS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
HLS.CA Yearly Total Debt VS Total AssetsHLS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • HLS has an Altman-Z score of -0.96. This is a bad value and indicates that HLS is not financially healthy and even has some risk of bankruptcy.
  • HLS has a Altman-Z score (-0.96) which is in line with its industry peers.
  • The Debt to FCF ratio of HLS is 3.13, which is a good value as it means it would take HLS, 3.13 years of fcf income to pay off all of its debts.
  • HLS's Debt to FCF ratio of 3.13 is fine compared to the rest of the industry. HLS outperforms 75.00% of its industry peers.
  • A Debt/Equity ratio of 0.73 indicates that HLS is somewhat dependend on debt financing.
  • The Debt to Equity ratio of HLS (0.73) is worse than 65.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 3.13
Altman-Z -0.96
ROIC/WACCN/A
WACC8.74%
HLS.CA Yearly LT Debt VS Equity VS FCFHLS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.11 indicates that HLS should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.11, HLS is doing worse than 81.25% of the companies in the same industry.
  • A Quick Ratio of 0.80 indicates that HLS may have some problems paying its short term obligations.
  • HLS's Quick ratio of 0.80 is on the low side compared to the rest of the industry. HLS is outperformed by 65.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.8
HLS.CA Yearly Current Assets VS Current LiabilitesHLS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. HLS.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 37.10% over the past year.
  • The Revenue has decreased by -1.98% in the past year.
  • The Revenue has been decreasing by -0.21% on average over the past years.
EPS 1Y (TTM)37.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.36%
Revenue growth 5Y-0.21%
Sales Q2Q%-2.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.93% on average over the next years. This is a very strong growth
  • HLS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.30% yearly.
EPS Next Y6.77%
EPS Next 2Y30.96%
EPS Next 3Y27.6%
EPS Next 5Y26.93%
Revenue Next Year5.52%
Revenue Next 2Y8.62%
Revenue Next 3Y8.08%
Revenue Next 5Y6.3%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HLS.CA Yearly Revenue VS EstimatesHLS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
HLS.CA Yearly EPS VS EstimatesHLS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. HLS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HLS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLS.CA Price Earnings VS Forward Price EarningsHLS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • 68.75% of the companies in the same industry are more expensive than HLS, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HLS indicates a rather cheap valuation: HLS is cheaper than 81.25% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.65
EV/EBITDA 8.68
HLS.CA Per share dataHLS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HLS's earnings are expected to grow with 27.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.96%
EPS Next 3Y27.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HLS.CA Dividend Analysis

5.1 Amount

  • No dividends for HLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HLS.CA Fundamentals: All Metrics, Ratios and Statistics

HLS THERAPEUTICS INC

TSX:HLS (4/17/2026, 7:00:00 PM)

4.65

+0.1 (+2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners43.33%
Inst Owner ChangeN/A
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap145.41M
Revenue(TTM)55.50M
Net Income(TTM)-12.43M
Analysts80
Price Target8.27 (77.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.87%
Min EPS beat(2)-69.73%
Max EPS beat(2)-32.01%
EPS beat(4)0
Avg EPS beat(4)-36.5%
Min EPS beat(4)-69.73%
Max EPS beat(4)-16.97%
EPS beat(8)1
Avg EPS beat(8)-20.13%
EPS beat(12)1
Avg EPS beat(12)-45.14%
EPS beat(16)1
Avg EPS beat(16)-50.43%
Revenue beat(2)1
Avg Revenue beat(2)-3.16%
Min Revenue beat(2)-6.61%
Max Revenue beat(2)0.3%
Revenue beat(4)1
Avg Revenue beat(4)-2.43%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)0.3%
Revenue beat(8)2
Avg Revenue beat(8)-4.07%
Revenue beat(12)3
Avg Revenue beat(12)-3.61%
Revenue beat(16)3
Avg Revenue beat(16)-4.57%
PT rev (1m)-0.92%
PT rev (3m)6.74%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-46.94%
EPS NY rev (3m)-125%
Revenue NQ rev (1m)-2.22%
Revenue NQ rev (3m)1.54%
Revenue NY rev (1m)-4.45%
Revenue NY rev (3m)-4.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.91
P/FCF 6.65
P/OCF 6.18
P/B 1.72
P/tB N/A
EV/EBITDA 8.68
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)0.7
FCFY15.03%
OCF(TTM)0.75
OCFY16.17%
SpS2.44
BVpS2.71
TBVpS-1.93
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -9.04%
ROE -20.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.83%
FCFM 28.69%
ROA(3y)-11.5%
ROA(5y)-9.8%
ROE(3y)-25.3%
ROE(5y)-20.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.78%
GM growth 5Y-2.65%
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 3.13
Debt/EBITDA 2.76
Cap/Depr 5.52%
Cap/Sales 2.17%
Interest Coverage N/A
Cash Conversion 104.88%
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.8
Altman-Z -0.96
F-Score6
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)2.06%
Cap/Depr(5y)1.78%
Cap/Sales(3y)0.83%
Cap/Sales(5y)0.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y6.77%
EPS Next 2Y30.96%
EPS Next 3Y27.6%
EPS Next 5Y26.93%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.36%
Revenue growth 5Y-0.21%
Sales Q2Q%-2.23%
Revenue Next Year5.52%
Revenue Next 2Y8.62%
Revenue Next 3Y8.08%
Revenue Next 5Y6.3%
EBIT growth 1Y40.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year514.29%
EBIT Next 3Y101.02%
EBIT Next 5Y62.37%
FCF growth 1Y99.36%
FCF growth 3Y-1.75%
FCF growth 5YN/A
OCF growth 1Y114.05%
OCF growth 3Y0.37%
OCF growth 5Y12.9%

HLS THERAPEUTICS INC / HLS.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HLS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA.


What is the valuation status for HLS stock?

ChartMill assigns a valuation rating of 3 / 10 to HLS THERAPEUTICS INC (HLS.CA). This can be considered as Overvalued.


How profitable is HLS THERAPEUTICS INC (HLS.CA) stock?

HLS THERAPEUTICS INC (HLS.CA) has a profitability rating of 2 / 10.


Can you provide the financial health for HLS stock?

The financial health rating of HLS THERAPEUTICS INC (HLS.CA) is 4 / 10.


Is the dividend of HLS THERAPEUTICS INC sustainable?

The dividend rating of HLS THERAPEUTICS INC (HLS.CA) is 0 / 10 and the dividend payout ratio is 0%.